Table 8 |
||||||
|
Methylated primary ER-negative and ER-positive tumors: T1c and T2/T3 subgroups |
||||||
| T1c (n = 48) |
T2/T3 (n = 82) |
|||||
|
|
||||||
| Gene |
ER negative (n = 24) |
ER positive (n = 24) |
P valuea |
ER negative (n = 41) |
ER positive (n = 41) |
P valuea |
|
|
||||||
| RASSF1A |
13 (54%) |
21 (88%) |
0.011 |
23 (56%) |
39 (95%) |
<0.0001 |
| CCND2 |
10 (42%) |
20 (83%) |
0.0029 |
16 (39%) |
25 (61%) |
0.0468 |
| GSTP1 |
3 (13%) |
6 (25%) |
NS |
1 (2%) |
13 (32%) |
0.0004 |
| TWIST |
6 (25%) |
12 (50%) |
NS |
11 (27%) |
20 (49%) |
0.0404 |
| APC |
9 (38%) |
8 (33%) |
NS |
11 (27%) |
23 (56%) |
0.0071 |
|
|
||||||
|
aχ2 test or Fisher's exact test was used appropriately. ER, estrogen receptor; NS, not significant. |
||||||
|
Sunami et al. Breast Cancer Research 2008 10:R46 doi:10.1186/bcr2098 |
||||||
